Nautilus Biotechnology, Inc. (NAUT) · Oct 26, 2026 · Earnings
Beat — EPS $(0.12) vs ~$0.14 expected loss; revenue $234K vs ~$206K–$210K consensus
Nautilus Biotechnology earnings narrowly beat Q3 expectations, while early oncology progress and new funding support the Voyager launch timeline.
Nautilus remains a development-stage proteomics company trying to turn its Voyager single-molecule platform into a commercial instrument-and-assay business. The market already knew the broad path: targeted proteoform services first, Voyager pre-orders around the commercial launch, and instrument availability in 2027; the latest company filing shifts resources toward proteoform applications because broadscale performance still needs improvement.
The quarter was a narrow earnings beat, not a commercial inflection. EPS was $(0.12) versus a published consensus near $(0.14), while revenue was $234,000 versus roughly $206,000–$210,000 expected. The revenue beat is economically small: the company says quarterly revenue was $0.2 million, primarily from grant work and Early Access services.
| Metric | Q3 2026 | Q3 2025 / expectation | Read |
|---|---|---|---|
| Revenue | $234K | $206K–$210K consensus | Above expectations, but still immaterial commercially |
| EPS | $(0.12) | $(0.14) consensus; $(0.11) prior year | Beat consensus, wider loss year over year |
| Operating expenses | $16.9M | $15.5M prior year | Up 10% |
| Nine-month operating cash use | $40.1M | $38.3M prior year | Burn increased |
| Cash, cash equivalents and investments | $114.3M | $156.1M at Dec. 31, 2025 | Still substantial, but down materially |
The real business update is incremental validation of the proteoform strategy. Management says its Nature Methods publication and early oncology assay results show that performance established with Tau is repeatable across additional targets, which supports the plan to build a broader assay portfolio rather than rely on one neuroscience use case. That is useful evidence for the commercialization story, but it is still technical validation—not customer adoption or product revenue. 〔0〕
SEEDS adds non-dilutive support and a credible application, but not near-term scale. Nautilus expects up to $6 million from a four-year ARPA-H-funded consortium to deploy Voyager in Alzheimer’s disease and cancer research. The funding helps extend the runway and provides an external research setting for the platform, but the filing explicitly says the amount could be reduced, delayed, or terminated.
Execution risk remains the central issue. Operating expenses rose 10% year over year to $16.9 million. Nine-month operating cash use also increased to $40.1 million from $38.3 million, while cash and investments fell to about $114 million from roughly $156 million at year-end. The balance sheet appears capable of funding the development program for now, but the company still needs to convert technical progress into pre-orders, shipments, and recurring assay demand.
The launch timeline was maintained rather than accelerated. Management continues to point to instrument availability in the middle of 2027, while the underlying commercialization plan remains pre-orders followed by initial targeted assays. The filing therefore improves confidence in the technology roadmap modestly, but does not materially shorten the path to meaningful revenue.
Bottom line: This is a narrow earnings beat with better technical and grant-related support for the Voyager story, but Nautilus remains a pre-commercial company. The important proof point is still whether 2027 pre-orders and instrument shipments turn validation into repeatable commercial demand.
Voyager pre-orders and mid-2027 instrument shipments
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!